Made available in DSpace on 2014-12-17T14:16:33Z (GMT). No. of bitstreams: 1
DianaQCF_DISSERT.pdf: 1652131 bytes, checksum: 3725280f12290a694c1544f741074448 (MD5)
Previous issue date: 2010-05-24 / Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico / The aim of this study was to determine the effects of the use of rosuvastatin in patients with
atherosclerosis, in relation to blood parameters of selenium and selenoproteins, and also
observe possible changes in gene expression of selenoproteins in these patients. The sample
consisted of 27 adult and elderly patients with a clinical diagnosis of coronary artery disease
undergoing angioplasty, treated at Natal Hospital Center hospital, Natal, RN. Patients were
treated with rosuvastatin 10 mg/day during four months. Anthropometric variables such as
body mass index (BMI) and Waist circumference (WC) were measured before and after
treatment, as well as lipid profile, blood glucose and liver enzymes (AST and ALT). The diet
of the patients was also analyzed using 24-hour diet recall. We analyzed the concentrations of
selenium in plasma and erythrocytes, and also the activity of Glutathione Peroxidase and gene
expression by Real Time PCR of selenoproteins GPx1, SelP1 and SelN1. Patients had mean
age of 61.0 ? 9.4 years, 59.3% were men and 40.7% were women. After four months of
treatment there was significant reduction of CA and, according to BMI, most were
overweight. The intake of macronutrients, cholesterol, polyunsaturated fatty acids,
monounsaturated and saturated was adequate, but the energy and fiber intake was below
the recommendations. Regarding the selenium intake was observed a high prevalence of
inadequacy. As expected, after treatment with rosuvastatin, a significant reduction in total
cholesterol, LDL and glucose, which was not observed for HDL. Selenium concentrations
in plasma and erythrocytes showed no changes, keeping within the established cutoffs. We
observed a significant increase in GPx enzyme activity and mRNA expression of GPX1 and
SEPN1, but not for gene SEPP1. Thus, it was found that treatment with rosuvastatin did not
reduce the expression of selenoproteins. More studies are needed to clarify the effects of
rosuvastatin on gene expression of selenoproteins in patients with atherosclerosis / Este trabalho tem como objetivo verificar os efeitos do uso da rosuvastatina em pacientes com
aterosclerose, em rela??o aos par?metros sangu?neos de sel?nio e selenoprote?nas, bem como
observar poss?veis altera??es na express?o g?nica de selenoprote?nas nesses pacientes. A
amostra foi constitu?da de 27 pacientes adultos e idosos com o diagn?stico cl?nico de doen?a
arterial coronariana submetidos ? angioplastia, atendidos no Natal Hospital Center, Natal, RN.
Os pacientes foram tratados com 10mg/dia de rosuvastatina durante 4 meses. Vari?veis
antropom?tricas, como ?ndice de Massa Corporal (IMC) e Circunfer?ncia Abdominal (CA),
foram medidas antes e ap?s o tratamento, bem como o perfil lip?dico, glicemia e enzimas
hep?ticas (AST e ALT). A dieta dos pacientes tamb?m foi analisada utilizando o Recordat?rio
alimentar de 24 horas. Foram analisadas as concentra??es do sel?nio no plasma e nos
eritr?citos, e tamb?m a atividade da enzima Glutationa Peroxidase e a express?o g?nica por
PCR em Tempo Real das selenoprote?nas GPx1, SelP1 e SelN1. Os pacientes apresentaram
idade m?dia de 61,0?9,4 anos, sendo 59,3% homens e 40,7% mulheres. Ap?s os quatro meses
de tratamento observou-se redu??o significativa da CA e, de acordo com o IMC, a maior parte
estava com sobrepeso. A ingest?o dos macronutrientes, colesterol, ?cidos graxos
polinsaturados, monoinsaturados e saturados foi adequada, por?m a de energia e fibras estava
abaixo das recomenda??es. Com rela??o a ingest?o de sel?nio foi observada uma alta
preval?ncia de inadequa??o. Como esperado, ap?s o tratamento com a rosuvastatina, houve
redu??o significativa do colesterol total e LDL, bem como da glicemia, o que n?o foi
observado para o HDL. As concentra??es de sel?nio no plasma e eritr?citos n?o apresentaram
altera??es, se mantendo dentro dos pontos de corte estabelecidos. Foi observado um aumento
significante na atividade enzim?tica da GPx e na express?o de mRNA do GPX1 e SEPN1,
mas n?o para o gene SEPP1. Dessa forma, foi verificado que o tratamento com a
rosuvastatina n?o diminuiu a express?o das selenoprote?nas. Mais estudos s?o necess?rios
para esclarecer os efeitos da rosuvastatina sobre a express?o g?nica de selenoprote?nas em
pacientes com aterosclerose
| Identifer | oai:union.ndltd.org:IBICT/oai:repositorio.ufrn.br:123456789/13489 |
| Date | 24 May 2010 |
| Creators | Ferreira, Diana Quit?ria Cabral |
| Contributors | CPF:17547644449, http://lattes.cnpq.br/1863589790139155, Rezende, Adriana Augusto de, CPF:05410395808, http://lattes.cnpq.br/4245215108740331, Freitas, Janaina Cristiana de Oliveira Crispim, CPF:91430364491, http://lattes.cnpq.br/2644540835478572, Cozzolino, Silvia Maria Franciscato, CPF:37694103868, http://lattes.cnpq.br/4835658625152534, Schwarzschild, L?cia de F?tima Campos Pedrosa |
| Publisher | Universidade Federal do Rio Grande do Norte, Programa de P?s-Gradua??o em Ci?ncias Farmac?uticas, UFRN, BR, Bioan?lises e Medicamentos |
| Source Sets | IBICT Brazilian ETDs |
| Language | Portuguese |
| Detected Language | Portuguese |
| Type | info:eu-repo/semantics/publishedVersion, info:eu-repo/semantics/masterThesis |
| Format | application/pdf |
| Source | reponame:Repositório Institucional da UFRN, instname:Universidade Federal do Rio Grande do Norte, instacron:UFRN |
| Rights | info:eu-repo/semantics/openAccess |
Page generated in 0.0021 seconds